Stock comparison
IDEXX Laboratories
Taysha Gene Therapies
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
IDXX
IDEXX Laboratories
Market cap
$44.12B
Sector
Healthcare
TSHA
Taysha Gene Therapies
Market cap
$1.37B
Sector
Healthcare
Overall winner
IDEXX Laboratories IDXX
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | IDXX | TSHA | Winner |
|---|---|---|---|
| Warren Buffett | 75B | 41D | IDXX |
| Benjamin Graham | 80A | 56D | IDXX |
| Philip Fisher | 75B | 61C | IDXX |
| Peter Lynch | 71B | 5F | IDXX |
| Joel Greenblatt | 83C | 2F | IDXX |
| Charlie Munger | 87A | 57D | IDXX |
| Terry Smith | 84A | 58D | IDXX |
Side-by-side metrics
| Metric | IDXX | TSHA |
|---|---|---|
| Market cap | $44.12B | $1.37B |
| P/E (TTM) | 39.0x | - |
| EV/EBIT | 31.6x | - |
| ROIC (TTM) | 40.66% | -47.3% |
| Gross margin | 62.05% | 88.22% |
| Net margin | 24.63% | -17.38% |
| Revenue CAGR 5y | 7.56% | - |
| EPS CAGR 5y | 10.79% | - |
| Debt / Equity | 0.7x | 0.1x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
IDXX leads on
- ROIC (TTM)40.66%vs -47.3%+186%
- Net margin24.63%vs -17.38%+101%
- Market cap$44.12Bvs $1.37B+97%
TSHA leads on
- P/E (TTM)-vs 39.0x+140%
- EV/EBIT-vs 31.6x+132%
- Debt / Equity0.1xvs 0.7x+88%
- Gross margin88.22%vs 62.05%+30%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.